Sheridan William P 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Mar 14, 2022
Insider Transaction Report
Form 4
Sheridan William P
SR VP - CMO
Transactions
- Exercise/Conversion
Common Stock
2022-03-10$3.22/sh+148,302$477,532→ 199,093 total - Sale
Common Stock
2022-03-10$16.87/sh−159,739$2,694,797→ 39,354 total - Sale
Common Stock
2022-03-10$17.64/sh−1,400$24,696→ 37,954 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2022-03-10−148,302→ 0 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (148,302 underlying)
Footnotes (2)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.53 to $17.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.53 to $17.79. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.